Study [mnob]
Efficacy [qlco]
Safety [hcpp]
Patients [podg]
Insulin [aapp, horm, phsu]
Dependent [qlco]
Diabetes Mellitus [dsyn]
Multi [qnco]
Center [spco]
randomized [resa]
Clinical Study [resa]
months [tmco]
Duration [tmco]
Performed [ftcn]
Patients [podg]
Hyperlipidaemia [dsyn]
Diabetes Mellitus, Non-Insulin-Dependent [dsyn]
Evaluate [ftcn]
Efficacy [qlco]
TOLERABILITY [resa]
Pravastatin [orch, phsu]
glycemia [carb]
Patients [podg]
eligible [idcn]
Trial [resa]
Fulfill [idcn]
Following [tmco]
criteria [inpr]
Plasma total cholesterol level [lbpr]
mg dl [qnco]
Stable [qlco]
glycemia [carb]
months [tmco]
Entry [inpr]
Patients [podg]
Received [qlco]
mg% [qnco]
Pravastatin [orch, phsu]
mg% [qnco]
Twice daily [tmco]
months [tmco]
Efficacy [qlco]
Evaluated [ftcn]
Patients [podg]
Pravastatin [orch, phsu]
Induced [ftcn]
Decrease [qlco]
Serum cholesterol level [lbpr]
Cholesterol, LDL [bacs, strd]
Total Cholesterol [lbpr]
Decreased [qnco]
mg dl [qnco]
mg dl [qnco]
3 Months [tmco]
Start [tmco]
treatment [ftcn]
Cholesterol, LDL [bacs, strd]
Decreased [qnco]
mg dl [qnco]
mg dl [qnco]
months [tmco]
treatment [ftcn]
Total Cholesterol [lbpr]
Cholesterol, LDL [bacs, strd]
mg dl [qnco]
P NOS [aapp, imft]
mg dl [qnco]
P NOS [aapp, imft]
cholesterol levels [lbpr]
Increased [qnco]
mg dl [qnco]
mg dl [qnco]
3 Months [tmco]
P NOS [aapp, imft]
mg dl [qnco]
months [tmco]
P NOS [aapp, imft]
Triglyceride [bacs, lipd]
Concentrations [menp]
Decreased [qnco]
mg dl [qnco]
mg dl [qnco]
3 Months [tmco]
mg dl [qnco]
months [tmco]
P NOS [aapp, imft]
Fasting [fndg]
Plasma glucose [lbpr]
Glycated haemoglobin [aapp, bacs]
Affected [ftcn]
Pravastatin [orch, phsu]
adverse events [fndg]
Observed [ftcn]
Cases [ftcn]
Always [tmco]
Mild [qlco]
Reversible [ftcn]
Pravastatin [orch, phsu]
Compliance [qnco]
Patients [podg]
Hyperlipidaemia [dsyn]
Diabetes Mellitus, Non-Insulin-Dependent [dsyn]
